AnaptysBio, Inc.'s (NASDAQ:ANAB) 45% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Simply Wall StNov 16 22:09

Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher

Yahoo FinanceNov 16 21:15

AnaptysBio Price Target Cut to $66.00/Share From $75.00 by JP Morgan

Dow JonesNov 12 23:51 · Ratings

AnaptysBio Is Maintained at Overweight by JP Morgan

Dow JonesNov 12 23:51 · Ratings

Is AnaptysBio (NASDAQ:ANAB) Using Debt In A Risky Way?

Simply Wall StNov 12 20:39

J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $66

Futu NewsNov 12 19:36 · Ratings